IHC diagnostics are now FDA approved for a variety of cancers including lung cancer, the most prevalent of the cancers. As such pathology labs receive large volumes of cancer biopsies that must be processed for IHC. Automation can greatly assist the pathologist as they become increasingly inundated with samples requiring mandatory FDA IHC assays. In addition, automation can improve reliability, reproducibility, and quality. Automaton of IHC workflow offers several advantages like protocol standardization, traceability, and walkaway operation.
BioGenex pioneered immunohistochemistry (IHC), including heat-induced antigen retrieval methods. The company continues to design, develop and commercialize molecular pathology systems for Tumor diagnosis, prognosis, precision medicine, and life science research. BioGenex prides itself on delivering cutting edge technology, years ahead of the competition, providing the finest systems for immunohistochemistry (IHC), in situ hybridization (ISH), Fluorescence ISH (FISH), special stains and in situ PCR. BioGenex systems and product performance are guaranteed: antibodies, probes, antigen retrieval, detection systems, and histology stains. We provide quality systems and are committed to best in class customer care.